Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

Table 2

Plasma levels of examined parameters and CA 15-3 in patients with breast cancer and in control groups.

Groups tested	CCL2	CCR2	CA 15-3
	(pg/mL)	(ng/mL)	(U/mL)
Breast cancer (median, range)
Stage I	192.81 (36.68-438.58)^b/f	1.34 (0.11-8.17)^a/f	17.15 (6.20-50.30)^a/b/f
Stage II	227.22 (1.45-1631.48)^b/f	0.93 (0.05-6.16)^a/b/f	17.60 (4.40-48.10)^a/b/f
Stage III and IV	398.55 (99.12-592.30)^a/b/c/d/f	0.92 (0.34-3.81)^a/b/f	27.75 (8.90-250.00)^a/b/c/d/f
Total group	228.34 (1.45-1631.48)^a/b/f	0.96 (0.05-8.17)^a/f	19.20 (4.40-250.00)^a/b/f
Control groups (median, range)
Benign breast tumor	118.64 (37.37-489.88)^e	1.82 (0.05-7.67)^e	14.00 (5.20-20.70)
Healthy women	155.17 (70.58-440.06)	3.45 (0.84-22.60)	13.40 (6.30-28.40)
Total control group	130.64 (37.37-489.88)	2.30 (0.05-22.60)	13.60 (5.20-28.40)

Notes:statistically significant when patients with BC compared with healthy women.Statistically significant when patients with BC compared with benign breast tumor group. Statistically significant when patients with BC stages III and IV compared with patients with BC stage I. Statistically significant when patients with BC stages III and IV compared with patients with BC stage II. Statistically significant when patients with benign breast tumor compared with healthy women. Statistically significant when patients with BC compared with total control group.